BiPER Therapeutics opens a new therapeutic pathway in the treatment of cancers and immunological disorders. BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy with a first focus on treating cancer patients with BPR001-615 a first-in-class selective BiP inhibitor at 6 months for first-in-patient clinical trials.

BiPER Therapeutics’ first clinical candidate BPR001-615 is a first-in-class oral small molecule to treat gastro-intestinal tumors by pushing cancer cells to burn out. BPR001-615 inhibits BiP, a key protein involved in cancer cell survival and associated with very poor prognosis of patients when overexpressed in tumors and in plasma of patients. BPR001-615 has been developed to treat the 50% of patients with high BiP expression through a precision medicine approach based on overexpression level of BiP in plasma of patients. BPR001-615 has been developed as an oral drug in monotherapy or in combination with standard of care to improve patient outcomes. In preclinical studies, patent-protected data demonstrate that BPR001-615 is effective in monotherapy outperforming standard of care and enhances a wide range of standard of care agents like chemotherapies, targeted therapies and immunotherapies. Very good tolerability profile of BPR001-615 has been confirmed by toxicology studies in rats and dogs with a confirmed high NOAEL and a therapeutic index of 10 in vivo.